4,901 trials
Paroxysmal Nocturnal Hemoglobinuria
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) Including by Severity — 2; 18; 2; 9 Participants
Concussion · Mild Traumatic Brain Injury
Primary: Safety of Higher Dosage of DHA — 0; 1 Participants
Safety Issues
Primary: OMI-20 Total Score Change From Baseline to Day 3 — 0.0; 0.0 score on a scale
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Including by Severity, During Single-dose Phase — 1; 2; 0; 1 Participants
Gastrointestinal and Gynecologic Malignancies
Primary: Rate of Detectable Peritoneal Metastases — 0; 2 percentage of lesions
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 21; 22; 11; 1 Participants
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms — 19; 18; 7; 15 Participants
Rheumatoid Arthritis
Primary: Maximum Observed Serum Concentration (Cmax) — 237.0341; 236.2882 ug/mL
Distress · Depression · Grief
Primary: Number of Participants Who Experienced Treatment-related Adverse Events as Assessed by NIH Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse…
Diarrhea
Primary: Number of Participants With Solicited Adverse Events — 2; 5; 9; 9 Participants
Malignant Melanoma
Primary: Number of Participants (%) With CTCAE Graded Adverse Events — 6 Participants
Hepatocellular Carcinoma
Primary: DLT Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 6; 4 Participants
Hernioplasty
Primary: Cmax — 663.412; 641.000 ng/ml
Parkinson Disease(PD)
Primary: Number of Related and Unrelated Adverse Events — 14; 3; 36 events
LQT2 Syndrome
Primary: Change From Baseline in Standard 12-Lead Electrocardiogram (ECG) Daytime QT Interval Corrected For Heart Rate Using The Fridericia Formula (QTcF) (AUC0-8)/8 at Day 3…